Page 10 - Cipla

Cipla partners with Genes2Me to launch Coronavirus RT PCR test kit

The kit is validated by the Indian Council of Medical Research (ICMR) and much more advanced than other RT PCR tests, the drug firm said

Winners of BS Awards 2021 capture India Inc's growth story

Business Standard Annual Awards for Corporate Excellence 2021 were announced this week. The winners were picked by an eight-member jury after extensive deliberations and capture India's growth story

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug

Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.

Cipla hits fresh all-time high in a volatile market; rallies 12% in 1 week

Going forward, significant momentum in Cipla will likely continue due to US gains on the back of peptide portfolio unlocking and possible approvals and launches of gRevlimid, gAdvair and gAbraxane

Pharma stocks surge on positive cues from Nifty healthcare, Cipla up 6%

Outlook for Indian drug exporters turned positive on prospects of firm exports amid the ongoing geo-political scenario, said analysts

Cipla gains 3%, hits record high; trades higher for 5th straight day

Analysts at ICICI Securities have maintained a 'buy' rating on the stock with target price of Rs 1,100 on the stock

Six Indian drug firms that are doing serious business in coronavirus times

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

Two Cipla promoters sell 20 mn shares; promoter group now holds 34.23%

Chairman Y K Hamied and Vice Chairman MK Hamied, who are non-executive directors and promoters, have sold 2,01,69,756 shares on Tuesday

Cipla slips 5% as 2.5% equity changes hands on the BSE

According to the disclosure made by the company, Y K Hamied, Chairman, and MK Hamied, Vice Chairman, sold 2,01,69,756 shares, representing 2.5 per cent of the total capital

Drugmaker Cipla to buy 32.49% stake in AMP Energy Green Eleven

AMP Energy Green Eleven was incorporated on November 21, 2020, and is engaged in the business of generating and supplying electrical power generated using solar energy

Sensex slips 581 pts amid hawkish US Fed, F&O expiry; Nifty holds 17,100

Sectorally, the Nifty PSU Bank index jumped a massive 5 per cent on the NSE, while the Nifty Bank and Private Bank indices added about a per cent each

Stocks to Watch: Axis Bank, Brightcom, Cipla, Federal Bank, Pidilite, IT

BHEL, Birlasoft, Canara Bank, Fino Payments Banks, LIC Housing Finance, MayMyIndia, McDowell Holdings, PNB, RBL Bank and Wockhardt to announce results today.

Multiple triggers across key markets may support Cipla's recent rally

In addition to the Q3 show, new launches offer upsides from current levels

Naina Lal Kidwai resigns from Cipla board

The veteran banker noted that she has put in her papers to fulfil several other responsibilities and professional commitments

Cipla Q3 PAT dips 2.6% at Rs 729 crore

Drug major Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021. The Mumbai-based company had posted a consolidated profit after tax (PAT) of Rs 748 crore in the October-December quarter of 2020-21 fiscal. Total revenue from operations, however, rose by 6 per cent to Rs 5,479 crore in the third quarter as compared with Rs 5,169 crore in the same period of last fiscal, Cipla said in a regulatory filing. "I am pleased to see the strong launch and commercial momentum across our core markets during the quarter. Our portfolio execution in branded markets of India and South Africa and strong respiratory traction driving our US generic franchise to a multi-quarter high quarter were key drivers," Cipla MD and Global CEO Umang Vohra noted. The unlocking of the company's first peptide asset, lanreotide injection is an important step in strengthening complex generics engine, inching up the drug .

Sensex snaps 5-day losing run, ends 367 pts up; Nifty holds 17,250

Bargain buying in banking and auto counters amid better-than-expected Q3 results by Axis Bank and Maruti Suzuki pushed the index 367 points higher at 57,858 level at close

InvaGen to continue to hold shares in Avenue Therapeutics: Cipla

In November 2018, Cipla had announced that InvaGen Pharmaceuticals Inc has entered into definitive agreements to acquire US-based speciality business firm Avenue Therapeutics for up to $215 million

Pharma shares trade firm; Laurus up 2%, Sun Pharma nears 52-week high

Sun Pharma, Cipla, Natco, Dr Reddy's, Torrent Pharma, Aurobindo Pharma and Strides have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from DCGI

Cipla receives EUA for oral antiviral drug to treat mild-to-moderate Covid

Cipla will soon make Cipmolnu 200 mg capsules, which will be available at all leading pharmacies and Covid treatment centres across the country